டர்க் சாவர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from டர்க் சாவர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In டர்க் சாவர் Today - Breaking & Trending Today
Fukushima: punkt zwrotny w polityce energetycznej Niemiec | Życie w Niemczech. Społeczeństwo, lifestyle, ciekawostki | DW dw.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from dw.com Daily Mail and Mail on Sunday newspapers.
Novartis International AG: Novartis reports positive topline results from second Phase III trial of Beovu in patients with diabetic macular edema , Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52) 1 In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase 1 Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the period of week 40 through week 52 was observed 1 1 Novartis intends to submit the data from KESTREL, together with the data from the pivotal Phase III KITE ....
Posted December 15th, 2020 for Novartis In Phase III KESTREL study , Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52) 1 In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase 1 Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the period of week 40 through week 52 was observed 1 1 Novartis intends to submit the data from KESTREL, together with the data from the pivotal Phase III KITE ....
In Phase III KESTREL study , Beovu (brolucizumab 6 mg) achieved its primary endpoint of non-inferiority to aflibercept 2 mg in change in best-corrected visual acuity (BCVA) at year one (week 52) 1 In a secondary endpoint, more than half of Beovu patients in the 6 mg arm were maintained on a three-month dosing interval through year one, following the loading phase 1 Significant improvement with Beovu 6 mg in change of central subfield thickness (CST) from baseline over the period of week 40 through week 52 was observed 1 1 Novartis intends to submit the data from KESTREL, together with the data from the pivotal Phase III KITE 2 study in DME, to health authorities in H1 2021 ....
RetinAI collaborates with Novartis to provide AI solutions for ophthalmology projects Dec 10 2020 RetinAI Medical AG announces a multi-year collaboration with Novartis Pharma AG under which RetinAI’s IT solutions and artificial intelligence tools shall be employed to support multiple projects in ophthalmology and digital health. Both companies have previously worked successfully on pilot projects in this disease area. Carlos Ciller, PhD, CEO RetinAI Medical AG. Related Stories The first project under the new Master Agreement will support a multi-center international clinical study involving patients with neovascular age-related macular degeneration (nAMD). The study is designed to investigate the influence of optical coherence tomography (OCT) image solutions using Artificial Intelligence (AI) on the assessment of disease activity. The study will be conducted in several clinical centers in numerous European countries and Canada, involving more than 500 patien ....